[1]
|
Levine, J.S. and Burakoff, R. (2011). Extraintestinal Manifestations of Inflammatory Bowel Disease. Gastroenterology and Hepatology, 7, 235-241.
|
[2]
|
Bamias, G., Nyce, M.R., De La Rue, S.A., et al. (2005) New Concepts in the PATHOPHYSIOLogy of Inflammatory Bowel Disease. Annals of Internal Medicine, 143, 895-904. https://doi.org/10.7326/0003-4819-143-12-200512200-00007
|
[3]
|
Katsanos, K.H. and Tsianos, E.V. (2002) The Kidneys in Inflammatory Bowel Disease. Annals of Gastroenterology, 15, 41-52.
|
[4]
|
Corica, D. and Romano, C. (2016) Renal Involvement in Inflammatory Bowel Diseases. Journal of Crohn’s and Colitis, 10, 226-235.
https://doi.org/10.1093/ecco-jcc/jjv138
|
[5]
|
Prattis, S. and Jurjus, A. (2015) Spontaneous and Transgenic Rodent Models of Inflammatory Bowel Disease. Laboratory Animal Research, 31, 47-68.
https://doi.org/10.5625/lar.2015.31.2.47
|
[6]
|
Xu, X.-R., Liu, C.-Q., Feng, B.-S., et al. (2014) Dysregulation of Mucosal Immune Response in Pathogenesis of Inflammatory Bowel Disease. World Journal of Gastroenterology, 20, 3255-3264. https://doi.org/10.3748/wjg.v20.i12.3255
|
[7]
|
Fuss, I.J., Heller, F., Boirivant, M., et al. (2004) Non Classical CD1d-Restricted NK T Cells That Produce IL-13 Characterize an Atypical Th2 Response in Ulcerative Colitis. Journal of Clinical Investigation, 113, 1490-1497.
https://doi.org/10.1172/JCI19836
|
[8]
|
Gálvez, J. (2014) Role of Th17 Cells in the Pathogenesis of Human IBD. ISRN inflammation, 928461. https://doi.org/10.1155/2014/928461
|
[9]
|
Rivera-Nieves, J., Bamias, G., Vidrich, A., et al. (2003) Emergence of Perianal Fistulizing Disease in the SAMP1/YitFc Mouse, a Spontaneous Model of Chronic Ileitis. Gastroenterology, 124, 972-982. https://doi.org/10.1053/gast.2003.50148
|
[10]
|
McGeachy, M.J., Bak-Jensen, K.S., Chen, Y., et al. (2007) TGF-Beta and IL-6 Drive the Production of IL-17 and IL-10 by T Cells and Restrain T(H)-17 Cell-Mediated Pathology. Nature Immunology, 8, 1390-1397. https://doi.org/10.1038/ni1539
|
[11]
|
Bettelli, E., Oukka, M. and Kuchroo, V.K. (2007) T(H)-17 Cells in the Circle of Immunity and Autoimmunity. Nature Immunology, 8, 345-350.
https://doi.org/10.1038/ni0407-345
|
[12]
|
Veny, M., Esteller, M., Ricart, E., et al. (2010) Late Crohn’s Disease Patients Present an Increase in Peripheral Th17 Cells and Cytokine Production Compared with Early Patients. Alimentary Pharmacology & Therapeutics, 31, 561-572.
https://doi.org/10.1111/j.1365-2036.2009.04209.x
|
[13]
|
Omenetti, S. and Pizarro, T.T. (2015) The Treg/Th17 Axis: A Dynamic Balance Regulated by the Gut Microbiome. Frontiers in Immunology, 6, 639.
https://doi.org/10.3389/fimmu.2015.00639
|
[14]
|
Ogura, Y., Bonen, D.K., Inohara, N., et al. (2001) A Frameshift Mutation in NOD2 Associated with Susceptibility to Crohn’s Disease. Nature, 411, 603-606.
https://doi.org/10.1038/35079114
|
[15]
|
Al Nabhani, Z., Dietrich, G., Hugot, J.P., et al. (2017) Nod2: The Intestinal Gate Keeper. PLOS Pathogens, 13, e1006177.
https://doi.org/10.1371/journal.ppat.1006177
|
[16]
|
Jurjus, A.R., Khoury, N.N. and Reimund, J.M. (2004) Animal Models of Inflammatory Bowel Disease. Journal of Pharmacological and Toxicological Methods, 50, 81-92.
|
[17]
|
Franke, A., Balschun, T., Karlsen, T.H., et al. (2008) Sequence Variants in IL10, ARPC2 and Multiple Other Loci Contribute to Ulcerative Colitis Susceptibility. Nature Genetics, 40, 1319-1323.
|
[18]
|
M?zes, G., Molnár, B., Tulassay, Z., et al. (2012) Changes of the Cytokine Profile in Inflammatory Bowel Diseases. World Journal of Gastroenterology, 18, 5848-5861.
|
[19]
|
Boirivant, M., Pallone, F., Di Giacinto, C., et al. (2006) Inhibition of Smad7 with a Specific Antisense Oligonucleotide Facilitates TGF-beta1-Mediated Suppression of Colitis. Gastroenterology, 131, 1786-1798.
|
[20]
|
Marek, A., Brodzicki, J., Liberek, A., et al. (2002) TGF-Beta (Transforming Growth Factor-Beta) in Chronic Inflammatory Conditions—A New Diagnostic and Prognostic Marker? Medical Science Monitor, 8, RA145-RA151.
|
[21]
|
Kallel, L., Nijaa, N., Fatma, L.B., Rais, L., et al. (2009) Familial Cases of Glomerulonephritis Complicating Crohn’s Disease. Journal of Crohn’s and Colitis, 3, 125-127.
|
[22]
|
Ko?ak, E., K?klü, S., Akbal, E., Huddam, B., et al. (2010) Development of Glomerulonephritis Early in the Course of Crohn’s Disease. Inflammatory Bowel Diseases, 16, 548-549. https://doi.org/10.1002/ibd.21044
|
[23]
|
Ambruzs, J.M., Walker, P.D. and Larsen, C.P. (2014) The Histopathologic Spectrum of Kidney Biopsies in Patients with Inflammatory Bowel Disease. Clinical Journal of the American Society of Nephrology, 9, 265-270.
https://doi.org/10.2215/CJN.04660513
|
[24]
|
Choi, J.Y., Yu, C.H., Jung, H.Y., Jung, M.K., et al. (2012) A Case of Rapidly Progressive IgA Nephropathy in a Patient with Exacerbation of Crohn’s Disease. BMC Nephrology, 13, 84.
|
[25]
|
Terasaka, T., Uchida, H.A., Umebayashi, R., Tsukamoto, K., Tanaka, K., Kitagawa, M., et al. (2016) The Possible Involvement of Intestine-Derived IgA1: A Case of IgA Nephropathy Associated with Crohn’s Disease. BMC Nephrology, 17, 122.
|
[26]
|
Wang, J., Anders, R.A., Wang, Y., et al. (2005) The Critical Role of LIGHT in Promoting Intestinal Inflammation and Crohn’s Disease. The Journal of Immunology, 174, 8173-8182.
|
[27]
|
Wang, J., Anders, R.A., Wu, Q., et al. (2004) Dysregulated LIGHT Expression on T Cells Mediates Intestinal Inflammation and Contributes to IgA Nephropathy. Journal of Clinical Investigation, 113, 826-835.
|
[28]
|
Kiryluk, K., Li, Y., Scolari, F., Sanna-Cherchi, S. and Choi, M. (2014) Discovery of New Risk Loci for IgA Nephropathy Implicates Genes Involved in Immunity against Intestinal Pathogens. Nature Genetics, 46, 1187-1196.
|
[29]
|
Onime, A., Agaba, E.I., Sun, Y., Parsons, R.B., et al. (2006) Immunoglobulin A Nephropathy Complicating Ulcerative Colitis. International Urology and Nephrology, 38, 349-353. https://doi.org/10.1007/s11255-006-0061-y
|
[30]
|
Takemura, T., Okada, M., Yagi, K., Kuwajima, H. and Yanagida, H. (2002) An Adolescent with IgA Nephropathy and Crohn Disease: Pathogenetic Implications. Pediatric Nephrology, 17, 863-866.
|
[31]
|
Pozzi, C., Andrulli, S., Del Vecchio, L., Melis, P., et al. (2004) Corticosteroid Effectiveness in IgA Nephropathy: Long-Term Results of a Randomized, Controlled Trial. Journal of the American Society of Nephrology, 15, 157-163.
|
[32]
|
Khosroshahi, H.T. and Shoja, M.M. (2006) Tubulointerstitial Disease and Ulcerative Colitis. Nephrology Dialysis Transplantation, 21, 2340.
|
[33]
|
Tokuyama, H., Wakino, S., Konishi, K., Hashiguchi, A., et al. (2010) Acute Interstitial Nephritis Associated with Ulcerative Colitis. Clinical and Experimental Nephrology, 14, 483-486. https://doi.org/10.1007/s10157-010-0294-z
|
[34]
|
Tadic, M., Grgurevic, I., Scukanec-Spoljar, M., et al. (2005) Acute Interstitial Nephritis due to Mesalazine. Nephrology, 10, 103-105.
|
[35]
|
Sato, H., Umemura, K., Yamamoto, T. and Sato, H. (2017) Interstitial Nephritis Associated with Ulcerative Colitis in Monozygotic Twins. BMJ Case Reports.
https://doi.org/10.1136/bcr-2016-218346
|
[36]
|
Stanton, B., Caza, T., Huang, D. and Beg, M.B. (2017) Tubulointerstitial Nephritis as the Initial Presentation of Crohn’s Disease and Successful Treatment with Infliximab. ACG Case Reports Journal, 4, e24.
|
[37]
|
Herrlinger, K.R., Noftz, M.K., Fellermann, K., et al. (2002) Minimal Renal Dysfunction in Inflammatory Bowel Disease Is Related to Disease Activity But Not to 5-ASA Use. Alimentary Pharmacology & Therapeutics, 15, 363-369.
https://doi.org/10.1046/j.1365-2036.2001.00940.x
|
[38]
|
Timmermans, S.A., Christiaans, M.H., Abdul-Hamid, M.A., et al. (2016) Granulomatous Interstitial Nephritis and Crohn’s Disease. Clinical Kidney Journal, 9, 556-559. https://doi.org/10.1093/ckj/sfw041
|
[39]
|
Heidt, J., Ooms, E.C., van der Werf, S.D. and Groeneveld, J.H. (2010) Tubulo-Interstitial Nephritis in Inflammatory Bowel Disease: Extra-Intestinal Manifestation or Drug Toxicity? Nederlands Tijdschrift Voor Geneeskunde, 154, A1647.
|
[40]
|
Fraser, J.S., Muller, A.F., Smith, D.J., Newman, D.J. and Lamb, E.J. (2001) Renal Tubular Injury Is Present in Acute Inflammatory Bowel Disease Prior to the Introduction of Drug Therapy. Alimentary Pharmacology & Therapeutics, 15, 1131-1137.
|
[41]
|
Kreisel, W., Wolf, L.M., Grotz, W. and Grieshaber, M. (1996) Renal Tubular Damage: An Extraintestinal Manifestation of Chronic Inflammatory Bowel Disease. European Journal of Gastroenterology & Hepatology, 8, 461-468.
|
[42]
|
Poulou, A.C., Goumas, K.E., Dandakis, D.C., Tyrmpas, I., et al. (2006) Microproteinuria in Patients with Inflammatory Bowel Disease: Is It Associated with the Diseaseactivity or the Treatment with 5-Aminosalicylic Acid? World Journal of Gastroenterology, 12, 739-746. https://doi.org/10.3748/wjg.v12.i5.739
|
[43]
|
Henry, C.B. and Duling, B.R. (2000) TNF-Alpha Increases Entry of Macromolecules into Luminal Endothelial Cell Glycocalyx. American Journal of Physiology-Heart and Circulatory Physiology, 279, H2815-H2823.
|
[44]
|
Mathy, N.L., Scheuer, W., Lanzend?rfer, M., et al. (2000) Interleukin-16 Stimulates the Expression and Production of Pro-Inflammatory Cytokines by Human Monocytes. Immunology, 100, 63-69.
|
[45]
|
Ranganathan, P., Jayakumar, C., Santhakumar, M., et al. (2013) Netrin-1 Regulates Colon-Kidney Cross Talk through Suppression of IL-6 Function in a Mouse Model of DSS-Colitis. American Journal of Physiology-Renal Physiology, 304, F1187-F1197.
|
[46]
|
Cury, D.B., Moss, A.C. and Schor, N. (2013) Nephrolithiasis in Patients with Inflammatory Bowel Disease in the Community. International Journal of Nephrology and Renovascular Disease, 6, 139-142.
|
[47]
|
Fagagnini, S., Heinrich, H., Rossel, J.B., Biedermann, L., et al. (2017) Risk Factors for Gallstones and Kidney Stones in a Cohort of Patients with Inflammatory Bowel Diseases. PLoS ONE, 12, e0185193.
|
[48]
|
Mukewar, S., Hall, P., Lashner, B.A., Lopez, R., et al. (2013) Risk Factors for Nephrolithiasis in Patients with Ileal Pouches. Journal of Crohn’s and Colitis, 7, 70-78.
|
[49]
|
Ganji-Arjenaki, M., Nasri, H. and Rafieian-Kopaei, M. (2017) Nephrolithiasis as a Common Urinary System Manifestation of Inflammatory Bowel Diseases; A Clinical Review and Meta-Analysis. Journal of Nephropathology, 6, 264-269.
https://doi.org/10.15171/jnp.2017.42
|
[50]
|
Nazzal, L., Puri, S. and Goldfarb, D.S. (2016) Enteric Hyperoxaluria: An Important Cause of End-Stage Kidney Disease. Nephrology Dialysis Transplantation, 3, 375-382. https://doi.org/10.1093/ndt/gfv005
|
[51]
|
Caudarella, R., Rizzoli, E., Pironi, L., et al. (1993) Renal Stone Formation in Patients with Inflammatory Bowel Disease. Scanning Microscopy, 7, 371-379.
|
[52]
|
Evan, A.P., Lingeman, J.E., Worcester, E.M., Bledsoe, S.B., et al. (2010) Renal Histopathology and Crystal Deposits in Patients with Small Bowel Resection and Calcium Oxalate Stone Disease. Kidney International, 78, 310-317.
|
[53]
|
Jonassen, J.A., Kohjimoto, Y., Scheid, C.R., et al. (2005) Oxalate Toxicity in Renal Cells. Urological Research, 33, 329-339. https://doi.org/10.1007/s00240-005-0485-3
|
[54]
|
Knauf, F., Asplin, J.R., Granja, I., Schmidt, I.M., et al. (2013) NALP3-Mediated Inflammation Isa Principal Cause of Progressive Renal Failure in Oxalate Nephropathy. Kidney International, 84, 895-901. https://doi.org/10.1038/ki.2013.207
|
[55]
|
Rodgers, A.L., Allie-Hamdulay, S., Jackson, G.E. and Sutton, R.A. (2014) Enteric Hyperoxaluria Secondary to Small Bowel Resection: Use of Computer Simulation to Characterize Urinary Risk Factors for Stone Formation and Assess Potential Treatment Protocols. Journal of Endourology, 28, 985-994.
|
[56]
|
Gkentzis, A., Kimuli, M., Cartledge, J., Traxer, O. and Biyani, C.S. (2016) Urolithiasis in Inflammatory Bowel Disease and Bariatric Surgery. World Journal of Nephrology, 5, 538-546.
|
[57]
|
Guardiola-Arévalo, A., Alcántara-Torres, M., Valle-Mu?oz, J., et al. (2011) Amyloidosis and Crohn’s Disease. Revista Espanola De Enfermedades Digestivas, 103, 268-274. https://doi.org/10.4321/S1130-01082011000500009
|
[58]
|
Cabezuelo, J.B., Egea, J.P., Ramos, F., et al. (2012) Infliximab in the Treatment of Amyloidosis Secondary to Crohn’s Disease. Nefrologia, 32, 385-388.
|
[59]
|
Powell-Tuck, J. (1986) Protein Metabolism in Inflammatory Bowel Disease. Gut, 27, 67-71. https://doi.org/10.1136/gut.27.Suppl_1.67
|
[60]
|
Dinarello, C.A., Simon, A. and van der Meer, J. (2012) Treating Inflammation by Blocking Interleukin-1 in a Broad Spectrum of Diseases. Nature Reviews Drug Discovery, 11, 633-652. https://doi.org/10.1038/nrd3800
|
[61]
|
Topaloglu, R., Batu, E.D., Orhan, D., Ozen, S. and Besbas, N. (2015) Anti-Interleukin 1 Treatment in Secondary Renal Amyloidosis Associated with Autoinflammatory Diseases. Pediatric Rheumatology Online Journal, 13, 149.
https://doi.org/10.1186/1546-0096-13-S1-P149
|
[62]
|
Azad Khan, A.K., Piris, J. and Truelove, S.C. (1977) An Experiment to Determine the Active Therapeutic Moiety of Sulphasalazine. The Lancet, 2, 892-895.
https://doi.org/10.1016/S0140-6736(77)90831-5
|
[63]
|
Rousseaux, C., Lefebvre, B., Dubuquoy, L., Lefebvre, P., et al. (2005) Intestinal Antiinflammatory Effect of 5-Aminosalicylic Acid Is Dependent on Peroxisome Proliferator-Activated Receptor-Gamma. The Journal of Experimental Medicine, 201, 1205-1215. https://doi.org/10.1084/jem.20041948
|
[64]
|
Iacucci, M., de Silva, S. and Ghosh, S. (2010) Mesalazine in Inflammatory Bowel Disease: A Trendy Topic Once Again? Canadian Journal of Gastroenterology, 24, 127-133. https://doi.org/10.1155/2010/586092
|
[65]
|
World, M.J., Stevens, P.E., Ashton, M.A. and Rainford, D.J. (1996) Mesalazine-Associated Interstitial Nephritis. Nephrology Dialysis Transplantation, 11, 614-621. https://doi.org/10.1093/oxfordjournals.ndt.a027349
|
[66]
|
Ransford, R.A. and Langman, M.J. (2002) Sulphasalazine and Mesalazine: Serious Adverse Reactions Re-Evaluated on the Basis of Suspected Adverse Reaction Reports to the Committee on Safety of Medicines. Gut, 51, 536-539.
https://doi.org/10.1136/gut.51.4.536
|
[67]
|
Muller, A.F., Stevens, P.E., McIntyre, A.S., Ellison, H. and Logan, R.F. (2005) Experience of 5-Aminosalicylate Nephrotoxicity in the United Kingdom. Alimentary Pharmacology & Therapeutics, 21, 1217-1224.
https://doi.org/10.1111/j.1365-2036.2005.02462.x
|
[68]
|
Schreiber, S., H?mling, J., Zehnter, E., Howaldt, S., Daerr, W., et al. (1997) Renal Tubular Dysfunction in Patients with Inflammatory Bowel Disease Treated with Aminosalicylate. Gut, 40, 761-766. https://doi.org/10.1136/gut.40.6.761
|
[69]
|
Corrigan, G. and Stevens, P.E. (2000) Review Article: Interstitial Nephritis Associated with the Use of Mesalazine in Inflammatory Bowel Disease. Alimentary Pharmacology & Therapeutics, 14, 1-6.
https://doi.org/10.1046/j.1365-2036.2000.00683.x
|
[70]
|
Cunliffe, R.N. and Scott, B.B. (2002) Review Article: Monitoring for Drug Side-Effects in Inflammatory Bowel Disease. Alimentary Pharmacology & Therapeutics, 16, 647-662. https://doi.org/10.1046/j.1365-2036.2002.01216.x
|
[71]
|
Verschueren, P., Lensen, F., Lerut, E., Claes, K., et al. (2003) Benefit of Anti-TNFalpha Treatment for Nephrotic Syndrome in a Patient with Juvenile Inflammatory Bowel Disease Associated Spondyloarthropathy Complicated with Amyloidosis and Glomerulonephritis. Annals of the Rheumatic Diseases, 62, 368-369.
https://doi.org/10.1136/ard.62.4.368
|
[72]
|
Sakellariou, G.T., Vounotrypidis, P. and Berberidis, C. (2007) Infliximab Treatment in Two Patients with Psoriatic Arthritis and Secondary IgA Nephropay. Clinical Rheumatology, 26, 1132-1133. https://doi.org/10.1007/s10067-006-0422-z
|
[73]
|
Sokumbi, O., Wetter, D.A., Makol, A. and Warrington, K.J. (2012) Vasculitis Associated with Tumor Necrosis Factor-α Inhibitors. Mayo Clinic Proceedings, 87, 739-745. https://doi.org/10.1016/j.mayocp.2012.04.011
|
[74]
|
Chin, G., Luxton, G. and Harvey, J.M. (2005) Infliximab and Nephrotic Syndrome. Nephrology Dialysis Transplantation, 20, 2824-2826.
https://doi.org/10.1093/ndt/gfi180
|
[75]
|
den Broeder, A.A., Assmann, K.J., van Riel, P.L. and Wetzels, J.F. (2003) Nephrotic Syndrome as a Complication of Anti-TNFalpha in a Patient with Rheumatoid Arthritis. The Netherlands Journal of Medicine, 61, 137-141.
|
[76]
|
Villemaire, M., Cartier, J.C., Mathieu, N., Maurizi, J., et al. (2014) Renal Sarcoid-Like Granulomatosis during Anti-TNF Therapy. Kidney International, 86, 215.
https://doi.org/10.1038/ki.2013.452
|
[77]
|
Yoo, Y.J., Chung, S.Y., Gu, D.H., Ko, G.J., et al. (2014) A Case of Late Onset-Acute Tubulointerstitial Nephritis with Infliximab and Mesalazine Treatment in a Patient with Crohn’s Disease. The Korean Journal of Gastroenterology, 63, 308-312.
https://doi.org/10.4166/kjg.2014.63.5.308
|
[78]
|
Dumitrescu, G., Dahan, K., Treton, X., Corcos, O., et al. (2015) Nephrotic Syndrome after Infliximab Treatment in a Patient with Ulcerative Colitis. Journal of Gastrointestinal and Liver Diseases, 24, 249-251.
|
[79]
|
Charles, P.J., Smeenk, R.J., De Jong, J., Feldmann, M. and Maini, R.N. (2000) Assessment of Antibodies to Double-Stranded DNA Induced in Rheumatoid Arthritis Patients Following Treatment with Infliximab, a Monoclonal Antibody to Tumor Necrosis Factor Alpha: Findings in Open-Label and Randomized Placebo-Controlled Trials. Arthritis & Rheumatology, 43, 2383-2390.
https://doi.org/10.1002/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D
|
[80]
|
Ziolkowska, M. and Maslinski, W. (2003) Laboratory Changes on Anti-Tumor Necrosis Factor Treatment in Rheumatoid Arthritis. Current Opinion in Rheumatology, 15, 267-273. https://doi.org/10.1097/00002281-200305000-00014
|
[81]
|
English, J., Evan, A., Houghton, D.C. and Bennett, W.M. (1987) Cyclosporine-Induced Acute Renal Dysfunction in the Rat. Evidence of Arteriolar Vasoconstriction with Preservation of Tubular Function. Transplantation, 44, 135-141.
https://doi.org/10.1097/00007890-198707000-00027
|
[82]
|
Kon, V., Sugiura, M., Inagami, T., Harvie, B.R., et al. (1990) Role of Endothelin in Cyclosporine-Induced Glomerular Dysfunction. Kidney International, 37, 1487-1491. https://doi.org/10.1038/ki.1990.139
|
[83]
|
Bobadilla, N.A. and Gamba, G. (2007) New Insights into the Pathophysiology of Cyclosporine Nephrotoxicity: A Role of Aldosterone. American Journal of Physiology-Renal Physiology, 293, F2-F9. https://doi.org/10.1152/ajprenal.00072.2007
|
[84]
|
Snanoudj, R., Royal, V., Elie, C., Rabant, M., et al. (2011) Specificity of Histological Markers of Long-Term CNI Nephrotoxicity in Kidney-Transplant Recipients under Low-Dose Cyclosporine Therapy. American Journal of Transplantation, 11, 2635-2646. https://doi.org/10.1111/j.1600-6143.2011.03718.x
|
[85]
|
Shang, M.H., Yuan, W.J., Zhang, S.J., Fan, Y. and Zhang, Z. (2008) Intrarenal Activation of Renin Angiotensin System in the Development of Cyclosporine a Induced Chronic Nephrotoxicity. Chinese Medical Journal, 121, 983-988.
|
[86]
|
Sereno, J., Rodrigues-Santos, P., Vala, H., Rocha-Pereira, P., Alves, R., et al. (2014) Transition from Cyclosporine-Induced Renal Dysfunction to Nephrotoxicity in an in Vivo Rat Model. International Journal of Molecular Sciences, 15, 8979-8997.
https://doi.org/10.3390/ijms15058979
|
[87]
|
Sandborn, W.J. (1995) Cyclosporine Therapy for Inflammatory Bowel Disease: Definitive Answers and Remaining Questions. Gastroenterology, 109, 1001-1003.
https://doi.org/10.1016/0016-5085(95)90413-1
|
[88]
|
Feagan, B.G., McDonald, J.W., Rochon, J., Laupacis, A., et al. (1994) Low-Dose Cyclosporine for the Treatment of Crohn’s Disease. The Canadian Crohn’s Relapse Prevention Trial Investigators. The New England Journal of Medicine, 330, 1846-1851. https://doi.org/10.1056/NEJM199406303302602
|
[89]
|
Sandborn, W.J., Tremaine, W.J. and Lawson, G.M. (1996) Clinical Response Does Not Correlate with Intestinal or Blood Cyclosporine Concentrations in Patients with Crohn’s Disease Treated with High-Dose Oral Cyclosporine. The American Journal of Gastroenterology, 91, 37-43.
|
[90]
|
Oikonomou, K.A., Kapsoritakis, A.N., Stefanidis, I. and Potamianos, S.P. (2011) Drug-Induced Nephrotoxicity in Inflammatory Bowel Disease. Nephron Clinical Practice, 119, c89-c94. https://doi.org/10.1159/000326682
|
[91]
|
Ogata, H., Matsui, T., Nakamura, M., Iida, M., et al. (2006) A Randomised Dose Finding Study of Oral Tacrolimus (FK506) Therapy in Refractory Ulcerative Colitis. Gut, 55, 1255-1262. https://doi.org/10.1136/gut.2005.081794
|
[92]
|
Wingard, J.R., Nash, R.A., Przepiorka, D., Klein, J.L., et al. (1998) Relationship of Tacrolimus (FK506) Whole Blood Concentrations and Efficacy and Safety after HLA-Identical Sibling Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 4, 157-163. https://doi.org/10.1016/S1083-8791(98)50005-5
|
[93]
|
Sandborn, W.J., Present, D.H., Isaacs, K.L., Wolf, D.C., et al. (2003) Tacrolimus for the Treatment of Fistulas in Patients with Crohn’s Disease: A Randomized, Placebo-Controlled Trial. Gastroenterology, 125, 380-388.
https://doi.org/10.1016/S0016-5085(03)00877-1
|
[94]
|
Hosoi, K., Arai, K., Matsuoka, K., Shimizu, H., et al. (2017) Prolonged Tacrolimus for Pediatric Gastrointestinal Disorder: Double-Edged Sword? Pediatrics International, 59, 588-592. https://doi.org/10.1111/ped.13211
|
[95]
|
Asada, A., Bamba, S., Morita, Y., Takahashi, K., et al. (2017) The Effect of CYP3A5 Genetic Polymorphisms on Adverse Events in Patients with Ulcerative Colitis Treated with Tacrolimus. Digestive and Liver Disease, 49, 24-28.
https://doi.org/10.1016/j.dld.2016.09.008
|
[96]
|
Meissner, Y., Pellequer, Y. and Lamprecht, A. (2006) Nanoparticles in Inflammatory Bowel Disease: Particle Targeting versus pH-Sensitive Delivery. International Journal of Pharmaceutics, 316, 138-143.
https://doi.org/10.1016/j.ijpharm.2006.01.032
|
[97]
|
Lamprecht, A., Yamamoto, H., Ubrich, N., Takeuchi, H., et al. (2005) FK506 Microparticles Mitigate Experimental Colitis with Minor Renal Calcineurin Suppression. Pharmaceutical Research, 22, 193-199.
https://doi.org/10.1007/s11095-004-1186-2
|